Incorporated in 2011, Glenmark Life Sciences is the leading manufacturer of Active Pharmaceutical Ingredients (APIs). The agency develops, manufactures, and materials terrific APIs for cardiovascular ailment (CVS), valuable nervous machine ailment (CNS), pain control, and diabetes, gastrointestinal issues, anti-infectives, and different therapeutic areas. It in addition operates in Contract Development and manufacturing operations (CDMO) to offer services to distinctiveness Pharmaceutical businesses.
Its merchandise are being bought in India and also expoted to multiple countries i.E. Europe, North America, Latin America, Japan, and so on. Currently, it has four production centers at Ankleshwar and Dahej in Gujarat and Mohol and Kurkumbh in Maharashtra State with an combination annual hooked up ability of 725.8 KL as of December 31, 2020.
Leading manufacturer of selected specialized APIs for continual healing regions like CVS, CNS, diabetes, and pain control.
Export merchandise in Europe, Latin America, North America, Japan, and the relaxation of the world.
Strong courting with main international widely wide-spread agencies.
Proven music document of strong financial performance.
High-first-class product production with R&D infrastructure.
Objects of the Issue
To make payment of outstanding buy consideration to the promoter for the spin-off of the API business from the promoter into the employer.
To finance capital expenditure requirements.
To meet widespread company purposes.
|Particulars||For the year/period ended (₹ in million)|
|Profit After Tax||3,515.81||3,130.98||1,955.92|
Glenmark Life Sciences IPO Details
|IPO Opening Date||Jul 27, 2021|
|IPO Closing Date||Jul 29, 2021|
|Issue Type||Book Built Issue IPO|
|Face Value||₹2 per equity share|
|IPO Price||₹695 to ₹720 per equity share|
|Market Lot||20 Shares|
|Min Order Quantity||20 Shares|
|Listing At||BSE, NSE|
|Issue Size||[.] Eq Shares of ₹2|
(aggregating up to ₹1,513.60 Cr)
|Fresh Issue||[.] Eq Shares of ₹2|
(aggregating up to ₹1,060.00 Cr)
|Offer for Sale||6,300,000 Eq Shares of ₹2|
(aggregating up to ₹453.60 Cr)
Glenmark Life Sciences IPO Tentative Timetable
The Glenmark Life Sciences IPO open date is Jul 27, 2021, and the close date is Jul 29, 2021. The issue may list on Aug 6, 2021.
|IPO Open Date||Jul 27, 2021|
|IPO Close Date||Jul 29, 2021|
|Basis of Allotment Date||Aug 3, 2021|
|Initiation of Refunds||Aug 4, 2021|
|Credit of Shares to Demat Account||Aug 5, 2021|
|IPO Listing Date||Aug 6, 2021|
Glenmark Life Sciences IPO Lot Size
The Glenmark Life Sciences IPO market lot size is 20 shares. A retail-individual investor can apply for up to 13 lots (260 shares or ₹187,200).
Glenmark Life Sciences IPO Promoter Holding
|Pre Issue Share Holding||100%|
|Post Issue Share Holding||82.84%|
Company Contact Information
Glenmark Life Sciences Limited
Plot No. 170-172, Chandramouli Industrial Estate,
Mohol Bazarpeth, Solapur 413 213,
Phone: +91 2189 234456/ +91 2189
Email: [email protected]